Law360 (January 12, 2021, 8:31 PM EST) — Attorneys for Allergan had a tough time Tuesday persuading the Patent Trial and Appeal Board that six patents covering the company’s injectable skin filler Juvederm are not obvious because they solved long-standing degradation problems with existing fillers, with one judge calling the argument “speculative.”
The board considered Prollenium US Inc.’s seven challenges to the patents during a marathon four-hour remote hearing Tuesday afternoon. Prollenium is hoping to get the patents invalidated to escape allegations from Allergan in Delaware federal court that its competing product, Revanesse Versa, infringes all six patents.
Juvederm, which is used to smooth wrinkles around the nose and mouth,…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
